Tags

Type your tag names separated by a space and hit enter

An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
Int Immunopharmacol. 2020 Aug; 85:106654.II

Abstract

The present state of diagnostic and therapeutic developmental race for vaccines against the SARS CoV-2 (nCOVID-19) focuses on prevention and control of this global pandemic which also represents a critical challenge to the global health community. Although development of novel vaccines can prevent the SARS CoV-2 infections, it is still impeded by several other factors and therefore novel approaches towards treatment and management of this disease is the urgent need. Passive immunotherapy plays a vital role as a possible alternative to meet this challenge and among various antibody sources, chicken egg yolk antibodies (IgY) can be used as an alternative to mammalian antibodies which have been previously studied against SARS CoV outbreak in China. In this review, we discuss the strategies for the use of chicken egg yolk (IgY) antibodies in the development of rapid diagnosis and immunotherapy against SARS CoV-2. Also, IgY antibodies have previously been used against various respiratory bacterial and viral infections in humans and animals. Compared to mammalian antibodies (IgG), chicken egg yolk antibodies (IgY) have greater binding affinity to specific antigens, ease of extraction and lower production costs, hence possessing remarkable pathogen-neutralizing activity of pathogens in respiratory and lungs. We provide an overall importance for the use of monoclonal chicken egg yolk antibodies (IgY) using phage display method describing their potential passive immunotherapeutic application for the treatment and prevention of SARS CoV-2 infection which is simple, fast and safe way of approach for treating patients effectively.

Authors+Show Affiliations

Department of Microbiology, PSG College of Arts & Science, Coimbatore, TN, India. Electronic address: rajeswaris69@yahoo.com.Department of Microbiology, PSG College of Arts & Science, Coimbatore, TN, India. Electronic address: ankitchoraria91@gmail.com.Department of Microbiology, PSG College of Arts & Science, Coimbatore, TN, India. Electronic address: amichela2000@gmail.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32512271

Citation

Somasundaram, Rajeswari, et al. "An Approach Towards Development of Monoclonal IgY Antibodies Against SARS CoV-2 Spike Protein (S) Using Phage Display Method: a Review." International Immunopharmacology, vol. 85, 2020, p. 106654.
Somasundaram R, Choraria A, Antonysamy M. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. Int Immunopharmacol. 2020;85:106654.
Somasundaram, R., Choraria, A., & Antonysamy, M. (2020). An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. International Immunopharmacology, 85, 106654. https://doi.org/10.1016/j.intimp.2020.106654
Somasundaram R, Choraria A, Antonysamy M. An Approach Towards Development of Monoclonal IgY Antibodies Against SARS CoV-2 Spike Protein (S) Using Phage Display Method: a Review. Int Immunopharmacol. 2020;85:106654. PubMed PMID: 32512271.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. AU - Somasundaram,Rajeswari, AU - Choraria,Ankit, AU - Antonysamy,Michael, Y1 - 2020/06/03/ PY - 2020/05/09/received PY - 2020/05/28/revised PY - 2020/05/28/accepted PY - 2020/6/9/pubmed PY - 2020/7/18/medline PY - 2020/6/9/entrez KW - IgY KW - Passive immunotherapy KW - Phage display KW - SARS CoV-2 KW - Spike protein (S) SP - 106654 EP - 106654 JF - International immunopharmacology JO - Int. Immunopharmacol. VL - 85 N2 - The present state of diagnostic and therapeutic developmental race for vaccines against the SARS CoV-2 (nCOVID-19) focuses on prevention and control of this global pandemic which also represents a critical challenge to the global health community. Although development of novel vaccines can prevent the SARS CoV-2 infections, it is still impeded by several other factors and therefore novel approaches towards treatment and management of this disease is the urgent need. Passive immunotherapy plays a vital role as a possible alternative to meet this challenge and among various antibody sources, chicken egg yolk antibodies (IgY) can be used as an alternative to mammalian antibodies which have been previously studied against SARS CoV outbreak in China. In this review, we discuss the strategies for the use of chicken egg yolk (IgY) antibodies in the development of rapid diagnosis and immunotherapy against SARS CoV-2. Also, IgY antibodies have previously been used against various respiratory bacterial and viral infections in humans and animals. Compared to mammalian antibodies (IgG), chicken egg yolk antibodies (IgY) have greater binding affinity to specific antigens, ease of extraction and lower production costs, hence possessing remarkable pathogen-neutralizing activity of pathogens in respiratory and lungs. We provide an overall importance for the use of monoclonal chicken egg yolk antibodies (IgY) using phage display method describing their potential passive immunotherapeutic application for the treatment and prevention of SARS CoV-2 infection which is simple, fast and safe way of approach for treating patients effectively. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/32512271/An_approach_towards_development_of_monoclonal_IgY_antibodies_against_SARS_CoV_2_spike_protein__S__using_phage_display_method:_A_review_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(20)31501-0 DB - PRIME DP - Unbound Medicine ER -